BioSpace News Archive

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today the presentation of preclinical data for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD).

Sandy J. Falk, MD, has been named Editor-in-Chief of the Merck Manuals, a digital medical reference available for free to all both online at www.MerckManuals.com and as mobile apps with versions for healthcare professionals and consumers.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive interim safety data from its Phase 1 clinical trial of EYP-1901.

Averix Bio is proud to announce that it has successfully completed an independent audit for 21 CFR Part 210 and Part 211 cGMP compliance of API phytocannabinoid CBD isolate in the U.S. as well as for ICH Q7 standards.

Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.

60 Degrees Pharmaceuticals, LLC (60P), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that a Data Safety Monitoring Board had recommended continuation of its clinical trial that is evaluating the safety and efficacy of ARAKODA® (tafenoquine).

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), today announced that it was selected to present new data from the company’s GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021.,

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a transition in the leadership of its Board of Directors.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on October 26, 2021, at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.